Post-earnings recap
Reported
Thu, Nov 3, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Relay Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.24% decline in its stock price following the earnings announcement. The lack of revenue figures and management commentary leaves investors with limited insights into the company's performance and future outlook. Overall, the results indicate challenges that may affect investor sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.76 | N/A | -7.80% |
| Revenue | — | N/A | — |
No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.